This topic contains 0 replies, has 1 voice, and was last updated by  MS News Today Moderator 5 months ago.

  • Author
    Posts
  • #17364
     MS News Today Moderator 
    Participant

    The U.S. Drug Enforcement Administration (DEA) has determined that the cannabidiol-based active ingredient of EHP-101, an investigational oral treatment for multiple sclerosis (MS) under development by Emerald Health Pharmaceuticals (EHP), should not be classified as a controlled substance.

    Click here to read more about this story.

    Do you agree with this decision?

You must be logged in to reply to this topic.

Copyright © 2017-2019 All rights reserved.

©2019 KLEO Template a premium and multipurpose theme from Seventh Queen

CONTACT US

We're not around right now. But you can send us an email and we'll get back to you, asap.

Sending
or

Log in with your credentials

or    

Forgot your details?

or

Create Account